Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 7
Submit an article Journal homepage
129
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

[211At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies

George S. Laszloa Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USAView further author information
,
Brenda M. Sandmaiera Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA;b Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USAView further author information
,
Allie R. Kehreta Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USAView further author information
,
Johnnie J. Orozcoa Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA;b Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USAView further author information
,
Donald K. Hamlinc Department of Radiation Oncology, University of Washington, Seattle, WA, USAView further author information
,
Shannon L. Dextera Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USAView further author information
,
Sheryl Y. T. Lima Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USAView further author information
,
Frances M. Colea Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USAView further author information
,
Jenny Huoa Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USAView further author information
,
D. Scott Wilburc Department of Radiation Oncology, University of Washington, Seattle, WA, USAView further author information
&
Roland B. Waltera Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA;d Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA;e Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA;f Department of Epidemiology, University of Washington, Seattle, WA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9268-3341View further author information
ORCID Icon show all
Pages 1335-1339 | Received 07 Mar 2023, Accepted 19 Apr 2023, Published online: 11 May 2023

References

  • Larson SM, Carrasquillo JA, Cheung NK, et al. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15(6):347–360.
  • Green DJ, Press OW. Whither radioimmunotherapy: to be or not to be? Cancer Res. 2017;77(9):2191–2196.
  • Shah NN, Sokol L. Targeting CD22 for the treatment of B-cell malignancies. Immunotargets Ther. 2021;10:225–236.
  • Aghevlian S, Boyle AJ, Reilly RM. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting alpha-particles or auger electrons. Adv Drug Deliv Rev. 2017;109:102–118.
  • Martins CD, Kramer-Marek G, Oyen WJG. Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges. Expert Opin Drug Deliv. 2018;15(2):185–196.
  • Eychenne R, Chérel M, Haddad F, et al. Overview of the most promising radionuclides for targeted alpha therapy: the “hopeful eight”. Pharmaceutics. 2021;13(6):906.
  • Lindén O, Bates AT, Cunningham D, et al. 227Th-labeled anti-CD22 antibody (Bay 1862864) in relapsed/refractory CD22-positive non-Hodgkin lymphoma: a first-in-human, phase I study. Cancer Biother Radiopharm. 2021;36(8):672–681.
  • Laszlo GS, Orozco JJ, Kehret AR, et al. Development of [(211)At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies. Leukemia. 2022;36(6):1485–1491.
  • Sullivan-Chang L, O'Donnell RT, Tuscano JM. Targeting CD22 in B-cell malignancies: current status and clinical outlook. BioDrugs. 2013;27(4):293–304.
  • Wynne J, Wright D, Stock W. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019;3(1):96–104.
  • Wilbur DS, Chyan MK, Nakamae H, et al. Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines. Bioconjug Chem. 2012;23(3):409–420.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.